Know Cancer

or
forgot password


Phase 4
60 Years
90 Years
Open (Enrolling)
Male
Prostate Cancer, Hyperplasia

Thank you

Trial Information


Inclusion Criteria:



Experimental group : Males between the ages of 60-90 years, with medical diagnosis of
prostate cancer according to both clinical and hematological examinations, before
receiving any medical treatment.

Control Group 1: Males between the ages of 60-90 years, with diagnosed benign prostate
hyperplasia -BPH.

Control Group 2: Males between the ages of 60-90 years, medically diagnosed as healthy.

Control Group 3: Males between the ages of 60-90 years, medically diagnosed with another
form of cancer, not prostate.

Exclusion Criteria:

Experimental group: Other known cancer or systemic infection. Control Group 1: Other known
cancer or systemic infection. Control Group 2:Past hematological disorders nor cancer
growth history. other known systemic infection, nor urinary tract infection. Patients
hospitalized for orthopedic injuries of any type who are otherwise free of urinary tract
infections.

Control Group 3:Other known systemic infection, nor urinary tract infection.

-

Type of Study:

Observational

Study Design:

Observational Model: Defined Population, Time Perspective: Longitudinal, Time Perspective: Prospective

Principal Investigator

Nina Kucherski, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Ziv Medical Center

Authority:

Israel: The Israel National Institute for Health Policy Research and Health Services Research

Study ID:

HP 7-251 S

NCT ID:

NCT00524823

Start Date:

August 2007

Completion Date:

Related Keywords:

  • Prostate Cancer
  • Hyperplasia
  • Prostate Cancer
  • Hyperplasia - BPH
  • FACS
  • Prostate Cancer, Hyperplasia - BPH, Malignancy
  • Hyperplasia
  • Prostatic Neoplasms

Name

Location